NCCN Guidelines® Insights: Bladder cancer, version 5.2018: Featured updates to the NCCN Guidelines Journal Article


Authors: Flaig, T. W.; Spiess, P. E.; Agarwal, N.; Bangs, R.; Boorjian, S. A.; Buyyounouski, M. K.; Downs, T. M.; Efstathiou, J. A.; Friedlander, T.; Greenberg, R. E.; Guru, K. A.; Hahn, N.; Herr, H. W.; Hoimes, C.; Inman, B. A.; Jimbo, M.; Kader, A. K.; Lele, S. M.; Meeks, J. J.; Michalski, J.; Montgomery, J. S.; Pagliaro, L. C.; Pal, S. K.; Patterson, A.; Petrylak, D. P.; Plimack, E. R.; Pohar, K. S.; Porter, M. P.; Preston, M. A.; Sexton, W. J.; Siefker-Radtke, A. O.; Tward, J.; Wile, G.; Johnson-Chilla, A.; Dwyer, M. A.; Gurski, L. A.
Article Title: NCCN Guidelines® Insights: Bladder cancer, version 5.2018: Featured updates to the NCCN Guidelines
Abstract: The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease. © JNCCN—Journal of the National Comprehensive Cancer Network.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 16
Issue: 9
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2018-09-01
Start Page: 1041
End Page: 1053
Language: English
DOI: 10.6004/jnccn.2018.0072
PROVIDER: scopus
PUBMED: 30181416
DOI/URL:
Notes: Review -- Export Date: 1 October 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Harry W Herr
    397 Herr
Related MSK Work